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behaviors, medication adherence, clinical factors, and quality of
care. Cross-product terms were speciﬁed to evaluate differential
effectiveness for subjects with differing clinical conditions includ-
ing renal insufﬁciency based on GFR, obesity, longer duration of
diabetes, and older age. RESULTS: A1C was lowered by 1.14
points (95%CI: 1.11–1.17) within one year after initiating new
therapy, but only 30.2% (95%CI: 29.2–31.1%) achieved target
(A1C < 7%). Mean A1C was 9.01 (8.98–9.04) prior to initia-
tion and 7.87 (7.85–7.90) at 3–12 months after baseline. While
baseline disease severity differed across initiators of each thera-
peutic class, there were no statistically signiﬁcant differences in
glycemic lowering across classes, or across clinical conditions.
CONCLUSIONS: Therapy initiation resulted in an impressive
population-level beneﬁt, similar in magnitude to that reported in
randomized trials. Nonetheless, most patients failed to achieve
glycemic targets after initiation possibly because providers had
delayed intensiﬁcation or patients failed to ﬁll earlier prescrip-
tions until they had advanced to very poor control. While no
population-level differences in response by therapy were
detected, in any one patient, differential response by class can
not be excluded. The substantial glycemic response following ini-
tiation suggests that providers are probably choosing therapies
for intensiﬁcation wisely, but that earlier addition of a new agent
may be beneﬁcial.
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OBJECTIVES: Previous studies have shown that for patients
with type 2 diabetes, self monitoring of blood glucose (SMBG)
can improve glycemic control (with HbA1c improvements of
0.3–0.6%, depending on treatment received). This in turn, can
reduce risks of disease complications. Because monitoring sup-
plies can have high acquisition costs, country-speciﬁc evaluations
of SMBG cost-effectiveness are needed. The aim of this analysis
was to estimate, within a US setting, the cost-effectiveness of
using SMBG. METHODS: A validated, published model for type
2 diabetes (The CORE Diabetes Model) was used to project
improvements in quality-adjusted life expectancy (QALE), long-
term costs and cost-effectiveness of SMBG. A series of Markov
models simulated the progression of diabetes-related complica-
tions (cardiovascular, neuropathy, renal and eye disease). Tran-
sition probabilities and HbA1c-dependent adjustments came
from major epidemiological studies. Costs of complications were
derived from published sources. From a US third party payer per-
spective, direct costs of diabetes complications and of SMBG
were projected over patient lifetimes. Outcomes were discounted
at 3% annually. RESULTS: Depending on type of treatment
(diet/exercise, oral medications, or insulin), greater glycemic
control with SMBG improved (discounted) QALE by 0.13 to
0.32 QALYs and increased total costs by $2089 to $4661 per
patient. The resulting incremental cost-effectiveness ratios
ranged from $13,848 to $35,880 per QALY gained, and were
well within current willingness-to-pay limits. SMBG was most
cost-effective in patients being treated with oral antidiabetic
medication, and those being treated with insulin therapy. CON-
CLUSIONS: Within the three treatment regimens examined, the
addition of SMBG was associated with increased glycemic
control and with improved clinical and economic long-term out-
comes. The incremental cost-effectiveness ratios were of magni-
tudes typically considered to indicate good value for money.
Additional comparative studies are needed to further assess Util-
ities and other standard outcomes associated with SMBG in
patients with type 2 diabetes.
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OBJECTIVES: Technological innovations may be cost-
increasing and quality-improving (CIQI), cost-saving and
quality-improving (dominant), cost-increasing and quality-
decreasing (dominated), or cost-saving and quality-decreasing
(CSQD). We endeavored to determine how cost-utility analyses
of new medical technologies are distributed across these cate-
gories. METHODS: We systematically searched computerized
databases including MEDLINE, HealthSTAR, CancerLit,
Current Contents and EconLit to identify cost-utility analyses
published in 2002 to 2003. Trained auditors summarized each
study using standardized forms. All costs were converted to 2002
US dollars. RESULTS: We identiﬁed 640 separate published cost
utility analyses. These papers compared 657 interventions
against a standard. Of analyzed interventions, 79.0% (519) were
CIQI, 13.5% (89) were dominant, 6.7% (44) were dominated,
but only 0.8% (5) were CSQD. Among CIQI interventions,
64.6% (335) had a cost-effectiveness ratio (CER) below $50,000
per QALY and 79.0% (410) had a CER below $100,000 per
QALY. Among CSQD interventions, 60% (3) had a CER below
$50,000 per QALY and 2 had a CER above $100,000 per QALY.
CONCLUSIONS: Most published cost-utility analyses are per-
formed on CIQI technologies, and most of these have a CER
below conventionally accepted thresholds. Cost-utility analyses
of CSQD technologies are extremely rare.
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OBJECTIVE: Solid organ transplants are among the most
resource intensive of treatments. There exists only limited knowl-
edge of the current costs of solid organ transplants in Canada
because existing studies were derived from single centres,
included different resource categories, covered different time
periods, and used different cost methodologies. The purpose
study was to derive population-based estimates of the direct
medical costs of kidney, liver, lung and heart transplans in British
Columbia (BC), Canada, from 1995 to 2003. METHODS:
Province wide resource utilization data were extracted from the
BC Transplant Society. This population-based registry includes
records of all persons undergoing solid organ transplantation in
BC. Unit cost data were obtained from publicly available
sources. Health resources categories included inpatient hospital
stays, outpatient visits, physician fees, laboratory and diagnostic
tests and immunosuppressant medications. Mean (standard devi-
ation (SD)) costs were derived separately for the transplant pro-
